[en] Glial fibrillary acidic protein (GFAP) is the main component of intermediate filaments of the cytoskeleton of astrocytes. Over more than four decades of fundamental and applied studies, GFAP achieved the status of the classical marker for astroglia. Our review deals with the analysis and systematization of the literature data describing the peculiarities of the structural organization of the molecules of this protein, its isoform composition, and changes in expression of the GFAP gene in the course of CNS ontogenesis; the hierarchical principle of the formation of glial intermediate filaments is also described. A great deal of information about key reactions of post-translational modifications of GFAP and their role in the functioning of the above-mentioned protein is conveyed. Based on the modern literature data, the limited proteolysis of GFAP is considered not only a stage of catabolic transformation of this protein but also a mechanism underlying regulation of the dynamic properties of the cytoskeleton in astroglial cells. It is believed that the main functions of GFAP are the maintenance of specific morphology of astrocytes, control of migration of these cells, and maintenance of the stability of their processes; however, more and more findings are indicative of the involvement of this protein in the processes of cellular signalling and modulation of neuron-to-glia interactions. GFAP as a component of intermediate filaments of the cytoskeleton plays a key role in the development of reactive astrocytosis, i.e., of a typical response of the CNS to injury. Overexpression of GFAP or suppression of its biosynthesis reflect modifications of the functional activity of astrocytes related to damage to the nerve tissue, metabolic abnormalities, and development of neurodegenerative states. Quantitative estimation of GFAP and of its breakdown products, as well as that of anti-GFAP autoantibodies in biological fluids, are at present used as significant criteria in the diagnostics of neurodegenerative pathologies. Non-canonical functions of GFAP, which it fulfills in non-astrocyte units, are indicative of functional polymorphism of this protein and need further investigations.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Tykhomyrov, А.A.; Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine
Pavlova, Oleksandra ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie humaine et pathologique
Nedzvetsky, V.S.; Oles’ Gonchar Dnipropetrovsk National University, Dnipropetrovsk, Ukraine
Language :
English
Title :
Glial Fibrillary Acidic Protein (GFAP): on the 45th Anniversary of Its Discovery
L. F. Eng, R. S. Ghirnikar, and Y. L. Lee, “Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000),” Neurochem. Res., 25, Nos. 9/10, 1439-1451 (2000).
Z. Yang and K. K. Wang, “Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker,” Trends Neurosci., 38, No. 6, 364-374 (2015).
L. F. Eng, J. J. Vanderhaeghen, A. Bignami, and B. Gerstl, “An acidic protein isolated from fibrous astrocytes,” Brain Res., 28, No. 2, 351-354 (1971).
C. T. Uyeda, L. F. Eng, and A. Bignami, “Immunological study of the glial fibrillary acidic protein,” Brain Res., 37, No. 1, 81-89 (1972).
A. Bignami, L. F. Eng, D. Dahl, and C. T. Uyeda, “Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence,” Brain Res., 43, No. 2, 429-435 (1972).
J. Middeldorp and E. M. Hol, “GFAP in health and disease,” Prog. Neurobiol., 93, No. 3, 421-443 (2011).
H. Deka, R. Sarmah, A. Sharma, and S. Biswas, “Modelling and characterization of glial fibrillary acidic protein,” Bioinformation, 11, No. 8, 393-400 (2015).
S. A. Lewis and N. J. Cowan, “Temporal expression of mouse glial fibrillary acidic protein mRNA studied by a rapid in situ hybridization procedure,” J. Neurochem., 45, 913-919 (1985).
M. V. Sofroniew and H. V. Vinters, “Astrocytes: biology and pathology,” Acta Neuropathol., 119, No. 1, 7-35 (2010).
L. Ben Haim, M. A. Carrillo-de Sauvage, K. Ceyzériat, and C. Escartin, “Elusive roles for reactive astrocytes in neurodegenerative diseases,” Front. Cell Neurosci., 9, 278 (2015).
L. F. Eng and R. S. Ghirnikar, “GFAP and astrogliosis,” Brain Pathol., 4, No. 3, 229-237 (1994).
E. M. Hol and M. Pekny, “Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system,” Curr. Opin. Cell Biol., 32, 121-130 (2015).
A. Petzold, “Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease,” Brain Res., 1600, 17-31 (2015).
C. M. Jacque, C. Vinner, M. Kujas, et al., “Determination of glial fibrillary acidic protein (GFAP) in human brain tumors,” J. Neurol. Sci., 35, No. 1, 147-155 (1978).
L. Schiff, N. Hadker, S. Weiser, and C. Rausch, “A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury,” Mol. Diagn. Ther., 16, No. 2, 79-92 (2012).
L. F. Eng, B. Gerstl, and J. J. Vanderhaeghen, “A study of proteins in old multiple sclerosis plaques,” Trans. Am. Soc. Neurochem., 1, 42 (1970).
K. A. Wunderlich, N. Tanimoto, A. Grosche, et al., “Retinal functional alterations in mice lacking intermediate filament proteins glial fibrillary acidic protein and vimentin,” FASEB J., 29, No. 12, 4815-4828 (2015).
K. R. Jessen, R. Thorpe, and R. Mirsky, “Molecular identity, distribution and heterogeneity of glial fibrillary acidic protein: an immunoblotting and immunohistochemical study of Schwann cells, satellite cells, enteric glia and astrocytes,” J. Neurocytol., 13, No. 2, 187-200 (1984).
D. Dahl, N. H. Chi, L. E. Miles, et al., “Glial fibrillary acidic (GFA) protein in Schwann cells: fact or artifact?” J. Histochem. Cytochem., 30, No. 9, 912-918 (1982).
G. B. Suarez-Mier and M. S. Buckwalter, “Glial fibrillary acidic protein-expressing glia in the mouse lung,” ASN Neuro, 7, No. 5, pii: 1759091415601636 (2015).
T. Clairembault, W. Kamphuis, L. Leclair-Visonneau, et al., “Enteric GFAP expression and phosphorylation in Parkinson’s disease,” J. Neurochem., 130, No. 6, 805-815 (2014).
S. Hassan, S. Syed, and S. I. Kehar, “Glial fibrillary acidic protein (GFAP) as a mesenchymal marker of early hepatic stellate cells activation in liver fibrosis in chronic hepatitis C infection,” Pak. J. Med. Sci., 30, No. 5, 1027-1032 (2014).
L. Danielyan, S. Zellmer, S. Sickinger, et al., “Keratinocytes as depository of ammonium-inducible glutamine synthetase: age- and anatomy-dependent distribution in human and rat skin,” PLoS One, 4, No. 2, e4416 (2009).
M. Murray, S. D. Wang, M. E. Goldberger, and P. Levitt, “Modification of astrocytes in the spinal cord following dorsal root or peripheral nerve lesions,” Exp. Neurol., 110, No. 3, 248-257 (1990).
S. S. Shah, V. S. Chandan, D. C. Wilbur, and K. K. Khurana, “Glial fibrillary acidic protein and CD57 immunolocalization in cell block preparations is a useful adjunct in the diagnosis of pleomorphic adenoma,” Arch. Pathol. Lab. Med., 131, No. 9, 1373-1377 (2007).
P. Redecker and J. Fechner, “Immunohistochemical study of cells positive for glial fibrillary acidic protein (GFAP) in the human pituitary gland, with special reference to folliculo-stellate cells,” Histochemistry, 91, No. 3, 227-234 (1989).
S. A. Reeves, L. J. Helman, A. Allison, and M. A. Israel, “Molecular cloning and primary structure of human glial fibrillary acidic protein,” Proc. Natl. Acad. Sci. USA, 86, No. 13, 5178-5182 (1989).
D. F. Condorelli, V. G. Nicoletti, V. Barresi, et al., “Structural features of the rat GFAP gene and identification of a novel alternative transcript,” J. Neurosci. Res., 56, No. 3, 219-228 (1999).
R. Thomsen, T. F. Daugaard, I. E. Holm, and A. L. Nielsen, “Alternative mRNA splicing from the glial fibrillary acidic protein (GFAP) gene generates isoforms with distinct subcellular mRNA localization patterns in astrocytes,” PLoS One, 8, No. 8, e72110 (2013).
D. F. Condorelli, V. G. Nicoletti, P. Dell’Albani, et al., “GFAPbeta mRNA expression in the normal rat brain and after neuronal injury,” Neurochem. Res., 24, No. 5, 709-714 (1999).
J. Blechingberg, I. E. Holm, K. B. Nielsen, et al., “Identification and characterization of GFAPkappa, a novel glial fibrillary acidic protein isoform,” Glia, 55, No. 5, 497-507 (2007).
W. Kamphuis, C. Mamber, M. Moeton, et al., “GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease,” PLoS One, 7, No. 8, e42823 (2012).
E. M. Hol, R. F. Roelofs, E. Moraal, et al., “Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms,” Mol. Psychiat., 8, No. 9, 786-796 (2003).
M. Prust, J. Wang, H. Morizono, et al., “GFAP mutations, age at onset, and clinical subtypes in Alexander disease,” Neurology, 77, No. 13, 1287-1294 (2011).
R. A. Quinlan, M. Brenner, J. E. Goldman, and A. Messing, “GFAP and its role in Alexander disease,” Exp. Cell Res., 313, No. 10, 2077-2087 (2007).
J. E. Goldman, H. H. Schaumburg, and W. T. Norton, “Isolation and characterization of glial filaments from human brain,” J. Cell Biol., 78, No. 2, 426-440 (1978).
D. Dahl, “Isolation and initial characterization of glial fibrillary acidic protein from chicken, turtle, frog and fish central nervous systems,” Biochim. Biophys. Acta, 446, No. 1, 41-50 (1976).
M. Sancho Tello, S. Valles, C. Montoliu, et al., “Developmental pattern of GFAP and vimentin gene expression in rat brain and in radial glial cultures,” Glia, 15, No. 2, 156-166 (1995).
C. F. Landry, G. O. Ivy, and I. R. Brown, “Developmental expression of glial fibrillary acidic protein mRNA in the rat brain analyzed by in situ hybridization,” J. Neurosci. Res., 25, No. 2, 194-203 (1990).
F. C. Gomes, D. Paulin, and V. Moura Neto, “Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation,” Braz. J. Med. Biol. Res., 32, No. 5, 619-631 (1999).
U. Wilhelmsson, C. Eliasson, R. Bjerkvig, and M. Pekny, “Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression,” Oncogene, 22, 3407-3411 (2003).
A. Zamoner, C. Funchal, M. C. Jacques-Silva, et al., “Thyroid hormones reorganize the cytoskeleton of glial cells through GFAP phosphorylation and Rhoa-dependent mechanisms,” Cell Mol. Neurobiol., 27, No. 7, 845-865 (2007).
S. Brahmachari, Y. K. Fung, and K. Pahan, “Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide,” J. Neurosci., 26, No. 18, 4930-4939 (2006).
J. Guo, D. Jia, and B. Jin, “Effects of glial cell line-derived neurotrophic factor intrathecal injection on spinal dorsal horn glial fibrillary acidic protein expression in a rat model of neuropathic pain,” Int. J. Neurosci., 122, No. 7, 388-394 (2012).
N. J. Laping, B. Teter, N. R. Nichols, et al., “Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors,” Brain Pathol., 4, No. 3, 259-275 (1994).
A. Michelucci, A. Bithell, M. J. Burney, et al., “The neurogenic potential of astrocytes is regulated by inflammatory signals,” Mol. Neurobiol., (2015).
A. L. Nielsen and A. L. Jørgensen, “Self-assembly of the cytoskeletal glial fibrillary acidic protein is inhibited by an isoform-specific C terminus,” J. Biol. Chem., 279, No. 40, 41537-41545 (2004).
M. Kornreich, R. Avinery, E. Malka-Gibor, et al., “Order and disorder in intermediate filament proteins,” FEBS Lett., 589, 19 Part A, 2464-2476 (2015).
R. L. Shoeman and P. Traub, “Assembly of intermediate filaments,” BioEssay, 15, No. 9, 605-611 (1993).
M. Inagaki, Y. Nakamura, M. Takeda, et al., “Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation,” Brain Pathol., 4, No. 3, 239-243 (1994).
M. Garbuglia, M. Verzini, and R. Donato, “Annexin VI binds S100A1 and S100B and blocks the ability of S100A1 and S100B to inhibit desmin and GFAP assemblies into intermediate filaments,” Cell Calcium, 24, No. 3, 177-191 (1998).
D. G. Graham, “Neurotoxicants and the cytoskeleton,” Curr. Opin. Neurol., 12, No. 6, 733-737 (1999).
V. S. Nedzvetskiĭ, G. A. Ushakova, S. G. Busygina, et al., “The effect of low doses of ionizing radiation on the intermediate filaments and the Ca2+-activated proteolysis system in the rat brain,” Radiobiologiia, 31, No. 3, 333-339 (1991).
T. T. Rohn, L. W. Catlin, and W. W. Poon, “Caspase-cleaved glial fibrillary acidic protein within cerebellar white matter of the Alzheimer’s disease brain,” Int. J. Clin. Exp. Pathol., 6, No. 1, 41-48 (2013).
G. Baydas, R. J. Reiter, V. S. Nedzvetskii, et al., “Altered glial fibrillary acidic protein content and its degradation in the hippocampus, cortex and cerebellum of rats exposed to constant light: reversal by melatonin,” J. Pineal Res., 33, No. 3, 134-139 (2002).
V. S. Nedzvetskiĭ, S. G. Busygina, V. A. Berezin, and A. I. Dvoretskiĭ, “The CNS syndrome. The characteristics of the intermediate filaments of the rat brain,” Radiobiologiia, 30, No. 2, 243-246 (1990).
H. Zetterberg, D. H. Smith, and K. Blennow, “Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood,” Nat. Rev. Neurol., 9, No. 4, 201-210 (2013).
A. M. Boutté, Y. Deng-Bryant, D. Johnson, et al., “Serum glial fibrillary acidic protein predicts tissue glial fibrillary acidic protein break-down products and therapeutic efficacy after penetrating ballistic-like brain injury,” J. Neurotrauma, 33, No. 1, 147-156 (2016).
J. W. Bigbee, D. D. Bigner, C. Pegram, and L. F. Eng, “Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor,” J. Neurochem., 40, No. 2, 460-467 (1983).
M. Takemura, H. Gomi, E. Colucci-Guyon, and S. Itohara, “Protective role of phosphorylation in turnover of glial fibrillary acidic protein in mice,” J. Neurosci., 22, No. 16, 6972-6979 (2002).
N. T. Snider and M. B. Omary, “Assays for posttranslational modifications of intermediate filament proteins,” Methods Enzymol., 568, 113-138 (2016).
J. H. Herskowitz, N. T. Seyfried, and D. M. Duong, “Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration,” J. Proteome Res., 9, No. 12, 6368-6379 (2010).
R. Rodnight, C. A. Gonçalves, S. T. Wofchuk, and R. Leal, “Control of the phosphorylation of the astrocyte marker glial fibrillary acidic protein (GFAP) in the immature rat hippocampus by glutamate and calcium ions: possible key factor in astrocytic plasticity,” Braz. J. Med. Biol. Res., 30, No. 3, 325-338 (1997).
N. T. Snider and M. B. Omary, “Post-translational modifications of intermediate filament proteins: mechanisms and functions,” Nat. Rev. Mol. Cell Biol., 15, No. 3, 163-177 (2014).
S. M. Sullivan, R. K. Sullivan, S. M. Miller, et al., “Phosphorylation of GFAP is associated with injury in the neonatal pig hypoxic-ischemic brain,” Neurochem. Res., 37, No. 11, 2364-2378 (2012).
Z. Jin, Z. Fu, J. Yang, et al., “Identification and characterization of citrulline-modified brain proteins by combining HCD and CID fragmentation,” Proteomics, 13, No. 17, 2682-2691 (2013).
D. Liu, C. Liu, J. Li, et al., “Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord,” PLoS One, 8, No. 12, e80779 (2013).
S. J. DeArmond, M. Fajardo, S. A. Naughton, and L. F. Eng, “Degradation of glial fibrillary acidic protein by a calcium dependent proteinase: an electroblot study,” Brain Res., 262, No. 2, 275-282 (1983).
Y. B. Lee, S. Du, H. Rhim, et al., “Rapid increase in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated by calcium influx and calpain I,” Brain Res., 864, No. 2, 220-229 (2000).
P. E. Mouser, E. Head, K. H. Ha, et al., “Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain,” Am. J. Pathol., 168, No. 3, 936-946 (2006).
M. H. Chen, T. L. Hagemann, R. A. Quinlan, et al., “Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation,” ASN Neuro, 5, No. 5, e00125 (2013).
L. Li, J. V. Welser, P. Dore-Duffy, et al., “In the hypoxic central nervous system, endothelial cell proliferation is followed by astrocyte activation, proliferation, and increased expression of the alpha 6 beta 4 integrin and dystroglycan,” Glia, 58, No. 10, 1157-1167 (2010).
M. Pekny, P. Levéen, M. Pekna, et al., “Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally,” EMBO J., 14, No. 8, 1590-1598.
W. Liedtke, W. Edelmann, P. L. Bieri, et al., “GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination,” Neuron, 17, No. 4, 607-615 (1996).
W. Liedtke, W. Edelmann, F. C. Chiu, et al., “Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion,” Am. J. Pathol., 152, No. 1, 251-259 (1998).
R. Tian, X. Wu, T. L. Hagemann, et al., “Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes,” J. Neuropathol. Exp. Neurol., 69, No. 4, 335-345 (2010).
M. Tardy, C. Fages, G. Le Prince, et al., “Regulation of the glial fibrillary acidic protein (GFAP) and of its encoding mRNA in the developing brain and in cultured astrocytes,” Adv. Exp. Med. Biol., 265, 41-52 (1990).
M. A. McCall, R. G. Gregg, R. R. Behringer, et al., “Targeted deletion in astrocyte intermediate filament (GFAP) alters neuronal physiology,” Proc. Natl. Acad. Sci. USA, 93, No. 13, 6361-6366 (1996).
M. Pekny, C. Eliasson, and C. L. Chien, “GFAPdeficient astrocytes are capable of stellation in vitro when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density,” Exp. Cell Res., 239, No. 2, 332-343 (1998).
M. V. Sofroniew, “Astrogliosis,” Cold Spring Harb. Perspect. Biol., 7, No. 2, a020420 (2014).
M. Pekny, U. Wilhelmsson, and M. Pekna, “The dual role of astrocyte activation and reactive gliosis,” Neurosci. Lett., 565, 30-38 (2014).
R. S. Ghirnikar, A. C. Yu, and L. F. Eng, “Astrogliosis in culture: III. Effect of recombinant retrovirus expressing antisense glial fibrillary acidic protein RNA,” J. Neurosci. Res., 38, No. 4, 376-385 (1994).
D. Triolo, G. Dina, I. Lorenzetti, et al., “Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage,” J. Cell Sci., 119, Part 19, 3981-3993 (2006).
M. Sugaya-Fukasawa, T. Watanabe, M. Tamura, et al., “Glial fibrillary acidic protein is one of the key factors underlying neuron-like elongation in PC12 cells,” Exp. Ther. Med., 2, No. 1, 85-87 (2011).
J. H. Kim, S. J. Kwon, M. C. Stankewich, et al., “Reactive protoplasmic and fibrous astrocytes contain high levels of calpain-cleaved alpha 2 spectrin,” Exp. Mol. Pathol., 100, No. 1, 1-7 (2016).
S. Safavi-Abbasi, J. R. Wolff, and M. Missler, “Rapid morphological changes in astrocytes are accompanied by redistribution but not by quantitative changes of cytoskeletal proteins,” Glia, 36, No. 1, 102-115 (2001).
B. D. Gulbransen and K. A. Sharkey, “Novel functional roles for enteric glia in the gastrointestinal tract,” Nat. Rev. Gastroenterol. Hepatol., 9, No. 11, 625-632 (2012).
G. B. von Boyen, M. Steinkamp, M. Reinshagen, et al., “Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia,” Gut, 53, No. 2, 222-228 (2004).
C. Laranjeira, K. Sandgren, N. Kessaris, et al., “Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury,” J. Clin. Invest., 121, No. 9, 3412-3424 (2011).
G. Baydas, V. S. Nedzvetskii, M. Tuzcu, et al., “Increase of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic rats: effects of vitamin E,” Eur. J. Pharmacol., 462, Nos. 1/3, 67-71 (2003).
V. S. Nedzvetsky, M. Tuzcu, A. Yasar, et al., “Effects of vitamin E against aluminum neurotoxicity in rats,” Biochemistry, 71, No. 3, 239-244 (2006).
K. Kaneko, A. Nakamura, K. Yoshida, et al., “Glial fibrillary acidic protein is greatly modified by oxidative stress in aceruloplasminemia brain,” Free Radical Res., 36, No. 3, 303-306 (2002).
C. S. Chiang, W. H. McBride, and H. R. Withers, “Radiation-induced astrocytic and microglial responses in mouse brain,” Radiother. Oncol., 29, No. 1, 60-68 (1993).
M. Carballo-Quintás, I. Martínez-Silva, C. Cadarso-Suárez, et al., “A study of neurotoxic biomarkers, c-fos and GFAP after acute exposure to GSM radiation at 900 MHz in the picrotoxin model of rat brains,” Neurotoxicology, 32, No. 4, 478-494 (2011).
D. Schiffer and V. Fiano, “Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses,” Amyotroph. Lateral. Scler. Other Motor. Neuron. Disord., 5, No. 1, 22-25 (2004).
E. C. Hirsch, T. Breidert, E. Rousselet, et al., “The role of glial reaction and inflammation in Parkinson’s disease,” Ann. N.Y. Acad. Sci., 991, 214-228 (2003).
K. L. Goodison, I. M. Parhad, C. L. White, et al., “Neuronal and glial gene expression in neocortex of Down’s syndrome and Alzheimer’s disease,” J. Neuropathol. Exp. Neurol., 52, No. 3, 192-198 (1993).
G. W. Ross, J. P. O’Callaghan, and D. S. Sharp, “Quantification of regional glial fibrillary acidic protein levels in Alzheimer’s disease,” Acta Neurol. Scand., 107, No. 5, 318-323 (2003).
S. S. Panter, J. D. McSwigan, and I. R. Sheppard, “Glial fibrillary acidic protein and Alzheimer’s disease,” Neurochem. Res., 10, No. 12, 1567-1576 (1985).
G. Levi, M. Patrizio, A. Bernardo, et al., “Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions,” Proc. Natl. Acad. Sci. USA, 90, No. 4, 1541-1545 (1993).
P. G. Kennedy, E. O. Major, R. K. Williams, and S. E. Straus, “Down-regulation of glial fibrillary acidic protein expression during acute lytic varicella-zoster virus infection of cultured human astrocytes,” Virology, 205, No. 2, 558-562 (1994).
L. Rinaman, J. P. Card, and L. W. Enquist, “Spatiotemporal responses of astrocytes, ramified microglia, and brain macrophages to central neuronal infection with pseudorabies virus,” J. Neurosci., 13, No. 2, 685-702 (1993).
S. E. Arnold, B. R. Franz, J. Q. Trojanowski, et al., “Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia,” Acta Neuropathol., 91, No. 3, 269-277 (1996).
E. Danzer, L. Zhang, A. Radu, et al., “Amniotic fluid levels of glial fibrillary acidic protein in fetal rats with retinoic acid induced myelomeningocele: a potential marker for spinal cord injury,” Am. J. Obstet. Gynecol., 204, No. 2, 178, e1-11 (2011).
P. E. Vos, M. van Gils, T. Beems, et al., “Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity,” Eur. J. Neurol., 13, No. 6, 632-638 (2006).
J. Steiner, H. Bielau, H. G. Bernstein, et al., “Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurons,” J. Neurol., Neurosurg., Psychiat., 77, No. 11, 1284-1287 (2006).
P. Wei, W. Zhang, L. S. Yang, et al., “Serum GFAP autoantibody as an ELISA-detectable glioma marker,” Tumour Biol., 34, No. 4, 2283-2292 (2013).
Z. Zhang, J. S. Zoltewicz, S. Mondello, et al., “Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products,” PLoS One, 9, No. 3, e92698 (2014).
C. F. Lucchinetti, Y. Guo, B. F. Popescu, et al., “The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica,” Brain Pathol., 24, No. 1, 83-97 (2014).
A. Ishigami, H. Masutomi, S. Handa, et al., “Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer’s disease brains,” J. Neurosci. Res., 93, No. 11, 1664-1674 (2015).
A. J. Mehta, “Alcoholism and critical illness: a review,” World J. Crit. Care Med., 5, No. 1, 27-35 (2016).
C. J. Wilhelm, J. G. Hashimoto, and M. L. Roberts, et al., “Astrocyte dysfunction induced by alcohol in females but not males,” Brain Pathol., 19, doi: 10.1111/bpa (2015).
H. Franke, H. Kittner, P. Berger, et al., “The reaction of astrocytes and neurons in the hippocampus of adult rats during chronic ethanol treatment and correlations to behavioral impairments,” Alcohol, 14, No. 5, 445-454 (1997).
C. Bull, W. A. Syed, S. C. Minter, and M. S. Bowers, “Differential response of glial fibrillary acidic protein-positive astrocytes in the rat prefrontal cortex following ethanol self-administration,” Alcohol. Clin. Exp. Res., 39, No. 4, 650-658 (2015).
K. P. Reis, L. Heimfarth, P. Pierozan, et al., “High postnatal susceptibility of hippocampal cytoskeleton in response to ethanol exposure during pregnancy and lactation,” Alcohol, 49, No. 7, 665-674 (2015).
S. Vallés, J. Pitarch, J. Renau-Piqueras, and C. Guerri, “Ethanol exposure affects glial fibrillary acidic protein gene expression and transcription during rat brain development,” J. Neurochem., 69, No. 6, 2484-2493 (1997).
C. Guerri and J. Renau-Piqueras, “Alcohol, astroglia, and brain development,” Mol. Neurobiol., 15, No. 1, 65-81 (1997).
A. A. Tikhomirov, V. S. Nedzvetskii, M. V. Lipka, et al., “Chronic alcoholization-induced damage to astroglia and intensification of lipid peroxidation in the rat brain: protector effect of hydrated form of fullerene C60,” Neurophysiology, 39, No. 2, 105-111 (2007).
A. A. Tykhomyrov, V. S. Nedzvetsky, V. K. Klochkov, and G. V. Andrievsky, “Nanostructures of hydrated C60 fullerene (C60HyFn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals,” Toxicology, 246, Nos. 2/3, 158-165 (2008).
А. A. Tikhomirov, G. V. Andrievsky, and V. S. Nedzvetsky, “Disorders in the cytoskeleton of astroglia and neurons in the rat brain induced by long-lasting exposure to ethanol and correction of these shifts by hydrated fullerene С60,” Neurophysiology, 40, No. 4, 279-287 (2008).
A. D. Thomson, “Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome,” Alcohol Alcohol. Suppl., 35, No. 1, 2-7 (2000).
Y. M. Parkhomenko, P. A. Kudryavtsev, S. Y. Pylypchuk, et al., “Chronic alcoholism in rats induces a compensatory response, preserving brain thiamine diphosphate, but the brain 2-oxo acid dehydrogenases are inactivated despite unchanged coenzyme levels,” J. Neurochem., 117, No. 6, 1055-1065 (2011).
A. Sharma, R. Bist, and P. Bubber, “Thiamine deficiency induces oxidative stress in brain mitochondria of Mus musculus,” J. Physiol. Biochem., 69, No. 3, 539-546 (2013).
S. S. Karuppagounder, H. Xu, Q. Shi, et al., “Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer’s mouse model,” Neurobiol. Aging, 30, No. 10, 1587-1600 (2009).
A. S. Hazell, “Astrocytes are a major target in thiamine deficiency and Wernicke’s encephalopathy,” Neurochem. Int., 55, Nos. 1/3, 129-135 (2009).
A. S. Hazell, K. V. Rao, N. C. Danbolt, et al., “Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial thalamus in experimental Wernicke’s encephalopathy,” J. Neurochem., 78, No. 3, 560-568 (2001).
P. Desjardins, K. G. Todd, A. S. Hazell, and R. F. Butterworth, “Increased ‘peripheral-type’ benzodiazepine receptor sites and mRNA in thalamus of thiamine-deficient rats,” Neurochem. Int., 35, No. 5, 363-369 (1999).
S. Afadlal, R. Labetoulle, and A. S. Hazell, “Role of astrocytes in thiamine deficiency,” Met. Brain Dis., 29, No. 4, 1061-1068 (2014).
R. Peters, “Ageing and the brain,” Postgrad. Med. J., 82, No. 964, 84-88 (2006).
J. P. David, F. Ghozali, C. Fallet-Bianco, et al., “Glial reaction in the hippocampal formation is highly correlated with aging in human brain,” Neurosci. Lett., 235, Nos. 1/2, 53-56 (1997).
J. A. Sloane, W. Hollander, D. L. Rosene, et al., “Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey,” Brain Res., 862, Nos. 1/2, 1-10 (2000).
Y. Wu, A. Q. Zhang, and D. T. Yew, “Age-related changes of various markers of astrocytes in senescence-accelerated mice hippocampus,” Neurochem. Int., 46, No. 7, 565-574 (2005).
M. Sabbatini, P. Barili, E. Bronzetti, et al., “Age-related changes of glial fibrillary acidic protein immunoreactive astrocytes in the rat cerebellar cortex,” Mech. Ageing Dev., 108, No. 2, 165-172 (1999).
I. Jalenques, A. Burette, E. Albuisson, and R. Romand, “Age-related changes in GFAP-immunoreactive astrocytes in the rat ventral cochlear nucleus,” Hear. Res., 107, Nos. 1/2, 113-124 (1997).
M. T. Berciano, M. A. Andres, E. Calle, and M. Lafarga, “Age-induced hypertrophy of astrocytes in rat supraoptic nucleus: a cytological, morphometric, and immunocytochemical study,” Anat. Rec., 243, No. 1, 129-144 (1995).
H. J. Jyothi, D. J. Vidyadhara, A. Mahadevan, et al., “Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta,” Neurobiol. Aging, 36, No. 12, 3321-3333 (2015).
S. Sharma, T. C. Nag, A. Thakar, et al., “The aging human cochlear nucleus: changes in the glial fibrillary acidic protein, intracellular calcium regulatory proteins, GABA neurotransmitter and cholinergic receptor,” J. Chem. Neuroanat., 56, 1-12 (2014).
A. Catalani, M. Sabbatini, C. Consoli, et al., “Glial fibrillary acidic protein immunoreactive astrocytes in developing rat hippocampus,” Mech. Ageing Dev., 123, No. 5, 481-490 (2002).
F. Amenta, E. Bronzetti, M. Sabbatini, and J. A. Vega, “Astrocyte changes in aging cerebral cortex and hippocampus: a quantitative immunohistochemical study,” J. Microscop. Res. Tech., 43, No. 1, 29-33 (1998).
N. Hayakawa, H. Kato, and T. Araki, “Age-related changes of astorocytes, oligodendrocytes and microglia in the mouse hippocampal CA1 sector,” Mech. Ageing Dev., 128, No. 4, 311-316 (2007).
I. K. Hwang, J. H. Choi, H. Li, et al., “Changes in glial fibrillary acidic protein immunoreactivity in the dentate gyrus and hippocampus proper of adult and aged dogs,” J. Vet. Med. Sci., 70, No. 9, 965-969 (2008).
C. E. Finch, “Neurons, glia, and plasticity in normal brain aging,” Adv. Gerontol., 10, 35-39 (2002).
A. Latour, B. Grintal, G. Champeil-Potokar, et al., “Omega-3 fatty acids deficiency aggravates glutamatergic synapse and astroglial aging in the rat hippocampal CA1,” Aging Cell., 12, No. 1, 76-84 (2013).
J. R. Day, A. T. Frank, J. P. O’Callaghan, et al., “The effect of age and testosterone on the expression of glial fibrillary acidic protein in the rat cerebellum,” Exp. Neurol., 151, No. 2, 343-346 (1998).
C. P. Anderson, I. Rozovsky, D. J. Stone, et al., “Aging and increased hypothalamic glial fibrillary acid protein (GFAP) mRNA in F344 female rats. Dissociation of GFAP inducibility from the luteinizing hormone surge,” Neuroendocrinology, 76, No. 2, 121-130 (2002).
